Current state of hematopoietic cell transplantation in CLL as smart therapies emerge

Mohamed A. Kharfan-Dabaja, Jessica El-Asmar, Farrukh T. Awan, Mehdi Hamadani, Ernesto Ayala

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Novel therapies targeting various kinases downstream of the B-cell receptor have emerged along with monoclonal antibodies and BCL-2 antagonists, and are changing the therapeutic landscape of chronic lymphocytic leukemia. However, cure remains unattainable unless eligible patients are offered an allogeneic hematopoietic cell transplant. Access to allogeneic hematopoietic cell transplantation has expanded considerably with availability of reduced intensity conditioning regimens which is capable offering durable remissions even in poor-risk disease. Encouraging data from ibrutinib and venetoclax in Del17p is challenging the notion of disease eradication as the ultimate therapeutic goal to a new concept of merely disease control. By favoring the non-transplant approach, patients should be aware that there are no established salvage therapies, yet, to rescue disease progression after ibrutinib. When disease eradication is the desirable approach, a reduced intensity conditioning allogeneic hematopoietic cell transplant is the preferred choice at this time.

Original languageEnglish (US)
Pages (from-to)54-66
Number of pages13
JournalBest Practice and Research: Clinical Haematology
Volume29
Issue number1
DOIs
StatePublished - Mar 1 2016
Externally publishedYes

Fingerprint

Cell Transplantation
Disease Eradication
Transplants
Salvage Therapy
B-Cell Chronic Lymphocytic Leukemia
Disease control
Transplantation (surgical)
Salvaging
Disease Progression
B-Lymphocytes
Phosphotransferases
Therapeutics
Monoclonal Antibodies
Cells
Availability
PCI 32765

Keywords

  • Allogeneic hematopoietic cell transplantation
  • B-cell receptor inhibitors
  • Reduced intensity conditioning

ASJC Scopus subject areas

  • Oncology
  • Clinical Biochemistry

Cite this

Current state of hematopoietic cell transplantation in CLL as smart therapies emerge. / Kharfan-Dabaja, Mohamed A.; El-Asmar, Jessica; Awan, Farrukh T.; Hamadani, Mehdi; Ayala, Ernesto.

In: Best Practice and Research: Clinical Haematology, Vol. 29, No. 1, 01.03.2016, p. 54-66.

Research output: Contribution to journalReview article

Kharfan-Dabaja, Mohamed A. ; El-Asmar, Jessica ; Awan, Farrukh T. ; Hamadani, Mehdi ; Ayala, Ernesto. / Current state of hematopoietic cell transplantation in CLL as smart therapies emerge. In: Best Practice and Research: Clinical Haematology. 2016 ; Vol. 29, No. 1. pp. 54-66.
@article{25bbc4f026fe4eef934c4a84a92ba87d,
title = "Current state of hematopoietic cell transplantation in CLL as smart therapies emerge",
abstract = "Novel therapies targeting various kinases downstream of the B-cell receptor have emerged along with monoclonal antibodies and BCL-2 antagonists, and are changing the therapeutic landscape of chronic lymphocytic leukemia. However, cure remains unattainable unless eligible patients are offered an allogeneic hematopoietic cell transplant. Access to allogeneic hematopoietic cell transplantation has expanded considerably with availability of reduced intensity conditioning regimens which is capable offering durable remissions even in poor-risk disease. Encouraging data from ibrutinib and venetoclax in Del17p is challenging the notion of disease eradication as the ultimate therapeutic goal to a new concept of merely disease control. By favoring the non-transplant approach, patients should be aware that there are no established salvage therapies, yet, to rescue disease progression after ibrutinib. When disease eradication is the desirable approach, a reduced intensity conditioning allogeneic hematopoietic cell transplant is the preferred choice at this time.",
keywords = "Allogeneic hematopoietic cell transplantation, B-cell receptor inhibitors, Reduced intensity conditioning",
author = "Kharfan-Dabaja, {Mohamed A.} and Jessica El-Asmar and Awan, {Farrukh T.} and Mehdi Hamadani and Ernesto Ayala",
year = "2016",
month = "3",
day = "1",
doi = "10.1016/j.beha.2016.08.001",
language = "English (US)",
volume = "29",
pages = "54--66",
journal = "Best Practice and Research in Clinical Haematology",
issn = "1521-6926",
publisher = "Bailliere Tindall Ltd",
number = "1",

}

TY - JOUR

T1 - Current state of hematopoietic cell transplantation in CLL as smart therapies emerge

AU - Kharfan-Dabaja, Mohamed A.

AU - El-Asmar, Jessica

AU - Awan, Farrukh T.

AU - Hamadani, Mehdi

AU - Ayala, Ernesto

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Novel therapies targeting various kinases downstream of the B-cell receptor have emerged along with monoclonal antibodies and BCL-2 antagonists, and are changing the therapeutic landscape of chronic lymphocytic leukemia. However, cure remains unattainable unless eligible patients are offered an allogeneic hematopoietic cell transplant. Access to allogeneic hematopoietic cell transplantation has expanded considerably with availability of reduced intensity conditioning regimens which is capable offering durable remissions even in poor-risk disease. Encouraging data from ibrutinib and venetoclax in Del17p is challenging the notion of disease eradication as the ultimate therapeutic goal to a new concept of merely disease control. By favoring the non-transplant approach, patients should be aware that there are no established salvage therapies, yet, to rescue disease progression after ibrutinib. When disease eradication is the desirable approach, a reduced intensity conditioning allogeneic hematopoietic cell transplant is the preferred choice at this time.

AB - Novel therapies targeting various kinases downstream of the B-cell receptor have emerged along with monoclonal antibodies and BCL-2 antagonists, and are changing the therapeutic landscape of chronic lymphocytic leukemia. However, cure remains unattainable unless eligible patients are offered an allogeneic hematopoietic cell transplant. Access to allogeneic hematopoietic cell transplantation has expanded considerably with availability of reduced intensity conditioning regimens which is capable offering durable remissions even in poor-risk disease. Encouraging data from ibrutinib and venetoclax in Del17p is challenging the notion of disease eradication as the ultimate therapeutic goal to a new concept of merely disease control. By favoring the non-transplant approach, patients should be aware that there are no established salvage therapies, yet, to rescue disease progression after ibrutinib. When disease eradication is the desirable approach, a reduced intensity conditioning allogeneic hematopoietic cell transplant is the preferred choice at this time.

KW - Allogeneic hematopoietic cell transplantation

KW - B-cell receptor inhibitors

KW - Reduced intensity conditioning

UR - http://www.scopus.com/inward/record.url?scp=84992187395&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84992187395&partnerID=8YFLogxK

U2 - 10.1016/j.beha.2016.08.001

DO - 10.1016/j.beha.2016.08.001

M3 - Review article

C2 - 27742072

AN - SCOPUS:84992187395

VL - 29

SP - 54

EP - 66

JO - Best Practice and Research in Clinical Haematology

JF - Best Practice and Research in Clinical Haematology

SN - 1521-6926

IS - 1

ER -